Parexel International CEO and leadership

Jamie Macdonald is Chief Executive Officer of Parexel. He has nearly 25 years of experience in leading global biopharmaceutical services companies.

Prior to joining Parexel, Mr. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014.

Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015.

Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018.

Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).

John Bell is a Chief Quality Officer at Parexel and is based in North Carolina.

MaryJo Zaborowski is Senior Vice President and Chief Information Officer at Parexel. She brings more than 20 years of executive technology leadership experience in the delivery of biomedical research and clinical development services for multiple Fortune 500 companies.

Prior to joining Parexel, Ms. Zaborowski directed end-to-end information and technology services for Janssen Pharmaceuticals’ research and development enterprise as Vice President and Chief Information Officer of R&D. Her previous experience also includes roles as Vice President and Information Officer of R&D at Eli Lilly; Senior Vice President, Enterprise Research and Analytics at Ingenix (UnitedHealth Group), and Senior Vice President, Global Head of R&D Informatics and Palo Alto Chief Information Officer at Roche Pharmaceuticals.

Across these roles, Ms. Zaborowski executed transformative technology innovation and established data science strongholds that enabled new business models and drove competitive advantage for each organization. Her strategy for Parexel includes the application of AI, automation, big data and biosensor technologies to enhance efficiencies, maximize productivity and accelerate drug development timelines.

Ms. Zaborowski holds a Bachelor's degree in Genetics from the University of California, Berkeley.

Ms. Howell leads manufacturer relationships and global sourcing for AmerisourceBergen -- her team is focused on the commercialization and support of brand, generic, specialty and consumer products. She brings to this role her consulting experience as a national authority on health care policy issues across sites of care and strategic impact for health care providers and manufacturers. She was a founder of Lash Group and served as President of Lash Group after it was acquired by AmerisourceBergen leading its growth from a boutique consulting firm to the leading provider of market access and reimbursement services in the country. She has led the acquisition and integration of several other consulting and manufacturer services businesses into AmerisourceBergen including Xcenda and TheraCom. She is a national speaker on health care policy trends and implications for the health care industry and has over 20 years of progressive leadership and management experience.

Greg Rush is Executive Vice President and Chief Financial Officer at Parexel and brings to the Company more than 25 years of experience leading global financial operations within the CRO and service industries.

Prior to joining Parexel, Mr. Rush served as Executive Vice President and Chief Financial Officer of Syneos Health, Inc. (formerly known as INC Research Holdings, Inc.) from August 2013 to February 2018. In that role, Mr. Rush oversaw the Company’s global financial operations, including Finance, Accounting, Tax, Treasury, Budgeting, M&A and Financial Planning, as well as all Information Technology functions.

Previously, Mr. Rush was Senior Vice President and CFO of Tekelec, a leading high-tech solutions and service provider that was acquired by Oracle. Mr. Rush also held positions of increasing responsibility at Siebel Systems, Quintiles Transnational Holdings, PricewaterhouseCoopers and Ernst & Young. In his roles, Mr. Rush has had repeated success in developing innovative financial management strategies, strong capital structures, high levels of operational support and sound corporate governance. He has experience in both private and public capital markets, completing more than 50 debt and equity financing transactions, including private equity transactions, initial public offerings (IPOs) and secondary offerings.

Mr. Rush is a Certified Public Accountant and holds a Bachelor of Science in Business Administration and a Master of Accounting from the University of North Carolina at Chapel Hill.

Mr. Crowley is Executive Vice President and General Counsel and Secretary of Parexel. In this capacity, he is responsible for the Company's worldwide legal, risk management, ethics & compliance and corporate governance.

Mr. Crowley brings to Parexel extensive commercial and corporate legal experience. He has provided counsel on a wide range of matters including commercial contracting, strategic alliances, corporate governance, mergers and acquisitions, compliance and ethics and intellectual property. Since joining Parexel in 2009, Mr. Crowley has held several key positions in the Legal & Risk Management organization, including most recently overseeing legal support for the Company’s commercial contracting and clinical operations organizations. Prior to joining Parexel, Mr. Crowley was Vice President and General Counsel at Netezza Corporation, a publicly-traded technology company. Mr. Crowley was previously with CA, Inc. and Concord Communications, Inc.

Mr. Crowley received his J.D. degree from Northeastern University School of Law. He also holds a Bachelor of Arts degree in History from the University of Miami and a Master of Arts degree in European History from the University of Rhode Island.

Jamie Macdonald is Chief Executive Officer of Parexel. He has nearly 25 years of experience in leading global biopharmaceutical services companies.

Prior to joining Parexel, Mr. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014.

Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015.

Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018.

Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).